Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · compa
The model's full reasoning — Q1 2022 call → NOThe task is to evaluate the earnings call transcript against two gates and return YES only if both gates are satisfied. Gate 1: Is there a positive, current development in the company's business that the Q&A discussion produces more concrete operating detail about than the prepared remarks contained? The main positive development highlighted is the 2-year data from the U.S. IDE clinical study, presented at the Aesthetics Meeting. Also, the Oaktree financing is a positive development. Let's look at the Q&A: - Josh Jennings asks about the Motiva IDE trial, specifically about capsular contracture rates and prepectoral vs subpectoral placement. Juan Jose answers with detail about why prepectoral is better, the history of textured implants, and the SmoothSilk surface. This is substantive detail about the technology and its implications. - Josh Jennings follows up on the FDA modular submission. Raj answers that they are ready to submit modules when FDA is ready, and they just submitted the second module. This is somewhat generic, not much new detail. - Phil Coover asks about U.S. timeline. Raj says they haven't endorsed a specific timeline. Not much new. - Phil Coover asks about China. Raj says they haven't moved on the position, and they are in communication with regulators, making progress. Some detail but not much new. - Marie Thibault asks about reactions to the 2-year data at the Aesthetics Meeting. Juan Jose answers about how other companies marketed against them, and now they have evidence. This is somewhat general, not very specific new operating detail. - Marie Thibault asks about Motiva Mia tools and the MDR process. Juan Jose says they are working with the notified body on final steps. Some detail. - Chris Cooley asks about guidance and headwinds. Raj talks about balance of business, Brazil being 17% of revenue. This is some detail. - Chris Cooley asks about Flora in the U.S. Juan Jose says plans are in progress, stay tuned. Not much new. - Zach Weiner asks about guidance and contributions from Flora/China. Raj says they have contributions but don't break it out. - Zach Weiner asks about inflationary pressures. Raj talks about slightly higher costs but good gross margin. The Q&A about the IDE data (the main positive development) - the first exchange with Josh Jennings does add substantive detail about the technology and why prepectoral is better.
The model's full reasoning — Q3 2022 call → NOWe need answer only YES or NO. Need evaluate both gates. Gate 1: positive current development, Q&A adds concrete operating detail beyond prepared remarks. Need identify. The call: revenue strong, growth, market share gains. Main positive developments: Mia Femtech launch prep, US IDE progress, Flora, China. Q&A probes: US FDA timeline, Europe demand, Mia commercialization, APAC, Flora, China, Mia pricing, 2023. Does Q&A add concrete operating detail? Let's examine. Prepared remarks already detailed: Mia investor day, Japan research numbers, plan commercialize H1 2023, regulatory updates, US IDE cohorts enrolled, three-year mark passed, submit fourth module this quarter, Flora launch, China approval H1 2023, post-market surveillance, etc. Q&A: Anthony asks US timeline. Management says not speculate, process continuous, no new specifics. Josh asks modular submission process: management says continuous, can ask questions, no new. George asks Mia MDD to MDR transition and Annex 16: management says Annex 16 expected this month, moving ahead, doing cases of Mia this week in Japan, early experience cases. That is new: doing cases this week in Japan. But is that substantive? It adds "doing cases of Mia this week here in Japan" - early experience cases. Also "we are currently in Japan" - not much. Marie asks APAC, Thailand symposium turnout: management says hundreds of plastic surgeons, gaining share, no specifics. Flora: management says independent study comparing device, patients responding more comfortable. No specifics. China: management says met partners, reinforced belief, no new. Mia pricing: management says based on willingness to pay, conservative. No new. Gate 1 requires across multiple exchanges, management answers add fresh concrete specifics. Here mostly restatement and generalities. The only new detail is Mia cases in Japan this week, but that's one exchange and not much. Also maybe "we are doing cases of Mia this week here in Japan" is current activity but not detailed. No multiple exchanges with additive substance. So Gate 1 likely NO. Gate 2: main positive development? Could be market share gains, Mia, US approval. Engine? Company's own product/technology. But if Gate 1 NO, answer NO. Need return NO. Thus final NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MNDY | monday.com Ltd. | Q4 2024 | 2024-05-15 | A |
| ZLAB | Zai Lab Limited | Q1 2024 | 2024-05-09 | B |
| YOU | Clear Secure, Inc. | Q1 2024 | 2024-05-08 | C+ |
| STIM | Neuronetics, Inc. | Q1 2024 | 2024-05-07 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q1 2024 | 2024-04-24 | A |
| CSGP | CoStar Group, Inc. | Q1 2024 | 2024-04-23 | B+ |
| SAP | SAP SE | Q1 2024 | 2024-04-22 | B |
| AREC | American Resources Corporation | Q4 2023 | 2024-03-28 | F |
| QRHC | Quest Resource Holding Corporation | Q4 2023 | 2024-03-12 | C+ |
| ALKT | Alkami Technology, Inc. | Q4 2023 | 2024-03-02 | A |
| MCW | Mister Car Wash, Inc. | Q4 2023 | 2024-02-21 | D |
| TYL | Tyler Technologies, Inc. | Q4 2023 | 2024-02-15 | C+ |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | B+ |
| SYY | Sysco Corporation | Q2 2024 | 2024-01-30 | B+ |
| STLD | Steel Dynamics, Inc. | Q4 2023 | 2024-01-24 | C+ |
| CSPI | CSP Inc. | Q4 2023 | 2023-12-12 | D |
| ATXS | Astria Therapeutics, Inc. | Q3 2023 | 2023-11-13 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| SG | Sweetgreen, Inc. | Q3 2023 | 2023-11-04 | D |
| CHRD | Chord Energy Corporation | Q3 2023 | 2023-11-02 | A |
| PLTR | Palantir Technologies Inc. | Q3 2023 | 2023-11-02 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| GSK | GSK plc | Q3 2023 | 2023-11-01 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| DNUT | Krispy Kreme, Inc. | Q2 2023 | 2023-08-10 | C |
| RBLX | Roblox Corporation | Q2 2023 | 2023-08-09 | C+ |
| PODD | Insulet Corporation | Q2 2023 | 2023-08-08 | B+ |
| MVST | Microvast Holdings, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| CIVI | Civitas Resources, Inc. | Q2 2023 | 2023-08-03 | B |
| IDT | IDT Corporation | Q3 2023 | 2023-06-05 | C |
| STIM | Neuronetics, Inc. | Q1 2023 | 2023-05-13 | B |
| VECO | Veeco Instruments Inc. | Q1 2023 | 2023-05-08 | B |
| LTH | Life Time Group Holdings, Inc. | Q1 2023 | 2023-04-25 | A |
| SCPH | scPharmaceuticals Inc. | Q4 2022 | 2023-03-22 | C+ |
| COCO | The Vita Coco Company, Inc. | Q4 2022 | 2023-03-08 | B |
| PBPB | Potbelly Corporation | Q4 2022 | 2023-03-02 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| LANC | Lancaster Colony Corporation | Q2 2023 | 2023-02-02 | B+ |
| NVS | Novartis AG | Q4 2022 | 2023-02-01 | B |
| RELL | Richardson Electronics, Ltd. | Q2 2023 | 2023-01-05 | B+ |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| MUR | Murphy Oil Corporation | Q3 2022 | 2022-11-03 | B+ |
| LPX | Louisiana-Pacific Corporation | Q3 2022 | 2022-11-01 | B+ |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | B+ |
| INVZ | Innoviz Technologies Ltd | Q2 2022 | 2022-08-10 | D |
| FLGT | Fulgent Genetics, Inc. | Q2 2022 | 2022-08-04 | C+ |
| GTHX | G1 Therapeutics, Inc. | Q1 2022 | 2022-08-03 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| TMUS | T-Mobile US, Inc. | Q2 2022 | 2022-07-27 | B+ |
| AZO | AutoZone, Inc. | Q3 2022 | 2022-05-24 | B+ |
| AXON | Axon Enterprise, Inc. | Q1 2022 | 2022-05-10 | B+ |
| VEV | Vicinity Motor Corp. | Q4 2021 | 2022-03-30 | D |
| HRTX | Heron Therapeutics, Inc. | Q4 2021 | 2022-02-28 | D |
| INCY | Incyte Corporation | Q4 2021 | 2022-02-08 | C+ |
| TMDX | TransMedics Group, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ATRC | AtriCure, Inc. | Q3 2021 | 2021-11-03 | C |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2021 | 2021-11-03 | C+ |
| ZI | ZoomInfo Technologies Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CHWY | Chewy, Inc. | Q2 2021 | 2021-09-01 | B |
| VVV | Valvoline Inc. | Q3 2021 | 2021-08-06 | B+ |
| TIGO | Millicom International Cellular S.A. | Q2 2021 | 2021-07-31 | B+ |
| SAP | SAP SE | Q2 2021 | 2021-07-21 | B+ |
| UPWK | Upwork Inc. | Q3 2018 | 2018-11-11 | B+ |
| MYO | Myomo, Inc. | Q3 2018 | 2018-11-05 | C |
| CFG | Citizens Financial Group, Inc. | Q3 2018 | 2018-10-19 | A |
| UAL | United Airlines Holdings, Inc. | Q3 2018 | 2018-10-17 | B+ |
| INSP | Inspire Medical Systems, Inc. | Q2 2018 | 2018-08-12 | A |
| REI | Ring Energy, Inc. | Q2 2018 | 2018-08-09 | B |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | B+ |
| RNG | RingCentral, Inc. | Q2 2018 | 2018-08-06 | A |
| FRPT | Freshpet, Inc. | Q2 2018 | 2018-08-06 | B+ |
| TSLA | Tesla, Inc. | Q2 2018 | 2018-08-02 | B |
| OOMA | Ooma, Inc. | Q1 2019 | 2018-05-22 | A |
| ZG | Zillow Group's | Q1 2018 | 2018-05-08 | C+ |
| QLYS | Qualys, Inc. | Q1 2018 | 2018-05-02 | B+ |
| CPS | Cooper-Standard Holdings Inc. | Q1 2018 | 2018-05-02 | B |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SYK | Stryker Corporation | Q1 2018 | 2018-04-26 | B+ |
| TNC | Tennant Company | Q4 2017 | 2018-02-22 | B |
| TMUS | T-Mobile US, Inc. | Q4 2017 | 2018-02-09 | B+ |
| NICE | NICE Ltd. | Q3 2017 | 2017-11-04 | A |
| SAMG | Silvercrest Asset Management Group Inc. | Q3 2017 | 2017-11-03 | A |
| VC | Visteon Corporation | Q3 2017 | 2017-10-28 | B+ |
| PRO | PROS Holdings, Inc. | Q3 2017 | 2017-10-26 | B+ |
| SRPT | Sarepta Therapeutics, Inc. | Q3 2017 | 2017-10-26 | C+ |
| CAL | Caleres, Inc. | Q2 2017 | 2017-08-29 | B+ |
| LITE | Lumentum Holdings Inc. | Q4 2017 | 2017-08-09 | B+ |
| FRPT | Freshpet, Inc. | Q2 2017 | 2017-08-07 | B+ |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | B+ |
| ADAP | Adaptimmune Therapeutics plc | Q1 2017 | 2017-05-10 | D |
| ISDR | Issuer Direct Corporation | Q1 2017 | 2017-05-06 | C |
| XPO | XPO Logistics, Inc. | Q1 2017 | 2017-05-04 | B |
| SRPT | Sarepta Therapeutics, Inc. | Q1 2017 | 2017-04-28 | D |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| SYK | Stryker Corporation | Q4 2016 | 2017-01-24 | C+ |
| MCS | The Marcus Corporation | Q3 2016 | 2016-10-27 | C+ |
| GSK | GSK plc | Q3 2016 | 2016-10-26 | B |
| VYGR | Voyager Therapeutics, Inc. | Q2 2016 | 2016-08-11 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| DGII | Digi International Inc. | Q3 2016 | 2016-07-28 | B |
| PAR | PAR Technology Corporation | Q1 2016 | 2016-05-04 | D |
| PM | Philip Morris International Inc. | Q1 2016 | 2016-04-19 | B+ |
RBLX · Q2 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in advertising, where management's prepared remarks mention live ads, 200 activations, 19% of top 100 with ad units, and some demand exceeding supply. In the Q&A, they add fresh specifics like pricing strategy (gentle now, floating later), new ad unit types, 12% of top 100 using portals, demand in 17-24 female cohort, self-serve options, and brand volume challenges. These details are operational and additive across multiple exchanges, meeting GATE 1 criteria. For GATE 2, advertising is driven by Roblox's own creation and control: 200 activations, portal ad units, self-serve platform, and rollout execution. It's not reliant on external industry tailwinds but on their platform improvements and brand engagement. This satisfies the primary engine condition.
SG · Q3 2023 → YESThe task is to evaluate two gates based on the Sweetgreen earnings call transcript and return YES only if both gates are YES, otherwise NO. YES The transcript shows a clear positive current development in Infinite Kitchen, with management's Q&A responses adding substantial new operational details—such as first-unit performance, customer experience improvements, margin leverage, AUV targeting, retrofit opportunities, and throughput optimizations—that go beyond the prepared remarks' high-level plans. This satisfies Gate 1 criteria for additive, substantive detail across multiple exchanges. For Gate 2, Infinite Kitchen is a proprietary technology the company developed and controls, with momentum driven by its own execution, customer adoption, and operational refinements rather than external tailwinds, making it the primary engine.
ALKT · Q4 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in the bank's market progress and add-on sales momentum, with Q&A providing substantial new operational details like specific backlog numbers, implementation timelines, product adoption rates, and customer-specific challenges that go beyond the prepared remarks. For GATE 2, the primary engine is Alkami's own platform, cloud-native architecture, and execution on replacements of legacy systems, which would largely continue even if external conditions shifted, as the company is actively winning share through its controlled rollout and product improvements.